Home › Merck to Acquire Cubist Pharmaceuticals for $102 Per Share in Cash
 

Keywords :   


Merck to Acquire Cubist Pharmaceuticals for $102 Per Share in Cash

2014-12-08 13:00:00| Merck.com - Corporate News

Dateline City: KENILWORTH, N.J. & LEXINGTON, Mass. Acquisition Augments Mercks Strong Foundation and Opportunity for Growth in Hospital Acute Care Market KENILWORTH, N.J. & LEXINGTON, Mass.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Cubist Pharmaceuticals, Inc. (NASDAQ:CBST) today announced that the companies have entered into a definitive agreement under which Merck will acquire Cubist for $102 per share in cash, which represents a 35 percent premium to Cubists average stock price for the most recent five trading days. Language: English Contact: MerckMedia Contacts:Lainie Keller, 908-406-1459orSteve Cragle, 908-740-1801orInvestor Contacts:Joe Romanelli, 908-740-1986orJustin Holko, 908-740-1879orCubistMedia Contact:Julie DiCarlo, 781-860-8063orInvestor Contact:Eileen C. McIntyre, 781-860-8100 Ticker Slug: Ticker: MRK Exchange: NYSE Ticker: CBST Exchange: NASDAQ read more

Tags: share cash acquire pharmaceuticals

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
22.09Tropical Depression Ten-E Forecast Discussion Number 1
22.09Tropical Depression Ten-E Graphics
22.09Tropical Depression Ten-E Wind Speed Probabilities Number 1
22.09Tropical Depression Ten-E Public Advisory Number 1
22.09Summary for Tropical Depression Ten-E (EP5/EP102024)
22.09Tropical Depression Ten-E Forecast Advisory Number 1
22.09Atlantic Tropical Weather Outlook
22.09Eastern North Pacific Tropical Weather Outlook
More »